GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Additional Paid-In Capital

InnoCare Pharma (FRA:33C) Additional Paid-In Capital : €1,524.18 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Additional Paid-In Capital?


InnoCare Pharma's quarterly additional paid-in capital declined from Jun. 2023 (€1,528.25 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€1,524.18 Mil).

InnoCare Pharma's annual additional paid-in capital increased from Dec. 2021 (€1,302.18 Mil) to Dec. 2022 (€1,591.85 Mil) but then declined from Dec. 2022 (€1,591.85 Mil) to Dec. 2023 (€1,524.18 Mil).


InnoCare Pharma Additional Paid-In Capital Historical Data

The historical data trend for InnoCare Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Additional Paid-In Capital Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial - - 1,302.18 1,591.85 1,524.18

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,591.85 1,528.25 - 1,524.18 -

InnoCare Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

InnoCare Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines